Program:
Overview of significant clinical aspects presented during the meeting, including:

• 02:01 Treatment optimisation in CML (Hochhaus EHA 2024)
• 03:25 Line-agnostic treatment recommendations according to clinical and biological data
• 04:38 Asciminib first-line ASC4 First (Hochhaus et al, EHA 2024)
• 09:21 Dasatinib dose optimisation - DasaHit (La Rosée P et al., EHA 2024)
• 12:30 Ponatinib dose optimisation - OPTIC (Apperley J et al., EHA 2024)
• 14:21 Ponatinib and azacytidine in myeloid blast phase (Rousselot P et al., EHA 2024)
  

Q&A Session can be found at the end of the biological overview.

If you have any questions or comments to the speaker, please email info@cml-foundation.org.